Minimally invasive gender-affirming procedures (MIGAPs), which aim to align gender identity and expression for transgender and gender-nonbinary patients in a way that is safe, effective, and semipermanent or reversible, are gaining in popularity. This article assesses the current amount of trainee exposure in clinic and didactic sessions in core procedural specialties nationwide via survey study of program directors. Low exposure of residents and fellows to MIGAPs was observed overall and a lack of procedure-specific education. In an effort to provide excellent patient care, promote cultural humility, and improve patients’ quality of life, further education regarding these procedures is necessary.
Bibliographical noteFunding Information:
S.T. Arron reports the following conflicts of interest: investigator for Leo Pharma, SunPharma, Menlo Therapeutics, Castle Biosciences, Genentech/Roche, Pfizer, Regeneron, Eli Lilly, PellePharm; consultant for Enspectra Health, Regeneron, Sanofi-Genzyme, Castle Creek Pharmaceuticals, SunPharma, Pennside Partners, Biossance, Gerson Lehrman Group, Rakuten Aspyrian. The remaining authors have nothing to disclose.
© 2019 Elsevier Inc.
- Cultural humility
- Gender-affirming procedures
- Medical education
- Minimally invasive procedures
PubMed: MeSH publication types
- Journal Article